Guidance for Industry on the Disclosure of Materials Provided to Advisory Committees in Connection with Open Advisory Committee Meetings Convened by the Center for Drug Evaluation and Research Beginning on January 1, 2000; Availability

Riepilogo

The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled ``Disclosure of Materials Provided to Advisory Committees in Connection with Open Advisory Committee Meetings Convened by the Center for Drug Evaluation and Research Beginning on January 1, 2000.'' This document provides guidance for industry on how FDA interprets the Federal Advisory Committee Act (FACA) with respect to the disclosure of materials provided to advisory committees convened by the Center for Drug Evaluation and Research (CDER).